30 results about "Propionyl-CoA" patented technology

Methods and cells for producing scattered branched-chain fatty acids are provided. For example, the invention provides a method for producing branched-chain fatty acid comprising a methyl on one or more even number carbons. The method comprises culturing a cell comprising an exogenous or overexpressed polynucleotide comprising a nucleic acid sequence encoding a polypeptide that catalyzes the conversion of propionyl-CoA to methylmalonyl-CoA and / or an exogenous or overexpressed polynucleotide comprising a nucleic acid sequence encoding a polypeptide that catalyzes the conversion of succinyl-CoA to methylmalonyl-CoA, under conditions allowing expression of the polynucleotide(s) and production of branched-chain fatty acid. The cell produces more branched-chain fatty acid comprising a methyl on one or more even number carbons than an otherwise similar cell that does not comprise the polynucleotide(s). A cell that produces branched-chain fatty acid and the branched-chain fatty acid also are provided.

Methods of treating seizure disorders by administration of a therapeutically effective amount of at least one precursor of propionyl-CoA in the absence of a ketogenic diet are provided. The present invention particularly applies to administration of triglyceride oils and preferably, triheptanoin and derivatives thereof.

The invention provides fermentative methods for producing n-propanol. The methods of the invention involve providing a suitable carbon source, a microorganism expressing the dicarboxylic acid pathway, reducing equivalents, and at least one gene coding for an enzyme that catalyzes the conversion of propionate / propionyl-CoA into n-propanol. The methods further involve contacting the carbon source and reducing equivalents with the microorganism under conditions favorable for the production of n-propanol. Also provided are methods for producing propylene and polypropylene from the n-propanol and microorganisms suitable for use in the methods of the invention.

The invention discloses recombination klebsiella pneumonia capable of co-producing 3-HP and P3HP, and a preparation method and application thereof. The recombination bacterium is obtained by introducing glycerol dehydratase gene, glycerol dehydratase reactivation enzyme gene, aldehyde dehydrogenase gene, propionyl coenzyme A synthetase gene and polyhydroxyalkanoate synthetase gene into a host recombination klebsiella pneumonia in which 1, 3-propylene glycol oxidoreductase gene and aldehyde reductase / alcohol dehydrogenase gene are knocked out. According to the technical scheme, the production cost of 3-hydroxypropionic acid and poly(3-hydroxypropionic acid) is reduced, and 3-hydroxypropionic acid and poly(3-hydroxypropionic acid) can be synthesized at the same time by taking a same thallus as the host.

The present invention relates to a method for treating and / or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.

The invention discloses a new synthesizing method of propionyl left-handed carnitine hydrochlorate, which comprises the following steps: 1. adopting inner salt of left-handed carnitine as raw material and propionic acid as solvent; adding propionyl chloride; heating to react; decompressing to evaporate propionic acid; adding acetone; stirring to disperse; cooling to evolve; sucking; drying to obtain rough product; 2. heating to dissolve rough product through alcohol or carbinol; sucking the filtrate; decompressing; distilling to condense; evaporating partial alcohol or carbinol; cooling; adding acetone to stir evenly; cooling to evolve; filtering; drying; obtaining the pure product.

The invention discloses genetic engineering bacteria for producing PHA (polyhydroxyalkanoates) from acetic acid and propionic acid as well as a construction method and an application of the genetic engineering bacteria. The method for preparing the engineering bacteria for producing PHA comprises the following steps: improving expression and / or activity of acetokinase, phosphotransacetylase, PHA synthetase, beta-ketothiolase, acetoacetyl-CoA reductase, succinate hemiacetal dehydrogenase, 4-hydroxybutyrate dehydrogenase, 4-hydroxybutyl CoA:CoA-transferase and propionyl CoA transferase in recipient bacteria, and reducing expression and / or activity of non-CoA-cycle succinate hemiacetal dehydrogenase in the recipient bacteria to obtain the engineering bacteria for producing PHA, wherein the recipient bacteria can grow with acetic acid as a carbon source. The prepared engineering bacteria are used for producing PHA with acetic acid as the carbon source, PHA yield can reach a higher level, and the bacteria have better industrial application prospect. The genetic engineering bacteria have great application value.

The invention belongs to the technical field of bioengineering, and particularly discloses a new method for producing high-yield ethyl lactate by using a saccharomyces cerevisiae strain and application of the strain. High-yield ethyl lactate is produced through the simultaneous heterologous expression of lactate dehydrogenase, propionyl-CoA transferase and alcohol acyltransferase in saccharomycescerevisiae. Pyruvate decarboxylase is completely knocked out from an original strain, and lactate dehydrogenase is overexpressed to obtain the yeast strain with a certain capability of generating L-lactic acid; a strong promoter TEF1 is selected and adopted for overexpressing propionyl-CoA transferase, a strong promoter PGK1 is selected and adopted for overexpressing alcohol acyltransferase, witha homothallic gene HO as an integration site, a copy number of propionyl-CoA transferase is increased, the saccharomyces cerevisiae strain capable of significantly increasing the yield of ethyl lactate is obtained, and the yield of ethyl lactate obtained by using the saccharomyces cerevisiae strain reaches 353.1 mg / L; compared with the original strain, the yield of isoamyl alcohol is decreased by49.9%, the yield of phenylethyl alcohol is decreased by 59.2%, and the new method meets the higher requirements of yeast in the related field of liquor and has broad application prospects.

Provided is a mutant of propionyl-CoA transferase from Clostridium propionicum that can convert lactate into lactyl-CoA with high efficiency in a method of preparing a polylactate (PLA) or PLA copolymer using microorganisms. Unlike conventional propionyl-CoA transferase which is weakly expressed in E. coli, when a mutant of propiony-CoA transferase from Clostridium propionicum is introduced into recombinant E. coli, lactyl-CoA can be supplied very smoothly, thereby enabling highly efficient preparation of polylactate (PLA) and PLA copolymer.

Disclosed is a recombinant microorganism, comprising endogenous enzymes that convert CO and / or CO2 to acetyl-CoA. The recombinant microorganism contains a heterologous nucleic acid sequence encoding one or more enzymes that allow the conversion of acetyl-CoA to an alkene with a main chain of 1 to 5 carbon atoms. The heterologous nucleic acid sequence comprises one or more coding sequences encoding one or more enzymes that catalyse the conversion of acetyl-CoA to crotonyl-CoA, and that further catalyse the conversion of crotonyl-CoA to an alkene; or one or more coding sequences encoding one or more enzymes that catalyse the conversion of acetyl-CoA to 3-methylcrotonyl-CoA, and that further catalyse the conversion of 3-methylcrotonyl-CoA to an alkene; or one or more coding sequences encoding one or more enzymes that catalyse the conversion of acetyl-CoA to propionyl-CoA, and that further catalyse the conversion of propionyl-CoA to an alkene. Each coding sequence is operationally linked to a transcriptional promoter.

The present invention provides a hydroxyacyl-coenzyme A dehydrogenase gene, an acyl-coenzyme A thiolase gene, genetically engineered strains and a use thereof. The hydroxyacyl-coenzyme A dehydrogenase gene encodes a protein (i) or (ii) as follows: (i) having an amino acid sequence according to SEQ ID NO 2; (ii) derived by substituting, deleting or inserting one or more amino acids in the amino acid sequence defined by (i) and having the same function as that of the protein of (i). The present invention constructs genetically engineered Mycobacterium strains lacking of a hydroxyacyl-coenzyme A dehydrogenase gene or an acyl-coenzyme A thiolase gene, which are used in the preparation of steroidal compounds, such as 1,4-BNA, 4-BNA, 9-OH-BNA, etc . . . Further, the invention improves the production efficiency and product quality of steroidal drug, improves the utilization of drug precursors, reduces the production costs, and provides the advantages of mild reaction conditions, environmentally friendly, and high economic and social benefits.

The invention provides recombinant bacteria for synthesizing succinic acid from a fixed amount of carbon dioxide, as well as a construction method and application of the recombinant bacteria, and belongs to the field of gene engineering and fermentation engineering. A recombinant bacteria host is escherichia coli, which can express a gene accADBC of acetyl-CoA carboxylase, a gene mcr of malonyl CoA reductase, a gene pcs of propionyl CoA synthase, a gene pcc of propionyl CoA carboxylase, a gene mcE of methylmalonyl-CoA isomerase, a gene mcM of methylmalonyl-CoA mutase and a gene sucCD of succinyl-coenzyme A synthase. According to the construction method, recombinant carriers pACYCDuet-accADBC-pcs and pETDuet-mcr-pcc-sucCD-mcEM are transformed into a host cell. The recombinant bacteria constructed through the construction method can adopt glucose serving as a unique carbon source to synthesize the succinic acid, and fermentation is performed for 48 hours, thus obtaining the succinic acid with the concentration of 6.06 g / L.

The present invention relates to the use of propionyl L-carnitine and the pharmaceutically acceptable salts thereof for the preparation of medicaments useful in the treatment of pathologies whose treatment gains a benefit from inducement of apoptosis, in particular blood vessels, such as restenosis after angioplasty or coronary stenting, or in particular tumors.

The invention discloses recombination klebsiella pneumonia capable of co-producing 3-HP and P3HP, and a preparation method and application thereof. The recombination bacterium is obtained by introducing glycerol dehydratase gene, glycerol dehydratase reactivation enzyme gene, aldehyde dehydrogenase gene, propionyl coenzyme A synthetase gene and polyhydroxyalkanoate synthetase gene into a host recombination klebsiella pneumonia in which 1, 3-propylene glycol oxidoreductase gene and aldehyde reductase / alcohol dehydrogenase gene are knocked out. According to the technical scheme, the production cost of 3-hydroxypropionic acid and poly(3-hydroxypropionic acid) is reduced, and 3-hydroxypropionic acid and poly(3-hydroxypropionic acid) can be synthesized at the same time by taking a same thallus as the host.

A microorganism capable of producing acrylic acid, comprising a genetic modification that increases activity of CoA acylating aldehyde dehydrogenase (ALDH) catalyzing conversion of 3-hydroxypropionaldehyde (3-HPA) to 3-hydroxy propionyl-CoA (3-HP-CoA) and a genetic modification that increases activity of 3-HP-CoA dehydratase catalyzing conversion of 3-HP-CoA to acrylyl-CoA in the microorganism in comparison with a cell that is not genetically engineered; as well as a method of producing the microorganism, and a method of producing acrylic acid using the same.

The invention discloses a Corynebacterium glutamicum and application thereof, belonging to the field of microorganisms. The Corynebacterium glutamicum was preserved in the China Center for Type Culture Collection on June 1, 2016, and the preservation number is CCTCC NO: M 2016303. The Corynebacterium glutamicum can accumulate more propionyl-CoA in cells, which is 15.8 times higher than that of ATCC13869, and can be used for the production of related metabolites using propionyl-CoA as a substrate. After the polyhydroxyalkanoate synthesis gene is introduced, the Corynebacterium glutamicum can synthesize PHBV, but the synthetic product is PHB in ATCC13869. The invention solves the current situation of producing PHBV by adding propionate or propionate from an exogenous source, realizes the direct production of PHBV in Corynebacterium glutamicum without adding propionate or propionate from an exogenous source, and reduces production costs.

The invention belongs to the technical field of bioengineering, and particularly discloses a new method for producing high-yield ethyl lactate by using a saccharomyces cerevisiae strain and application of the strain. High-yield ethyl lactate is produced through the simultaneous heterologous expression of lactate dehydrogenase, propionyl-CoA transferase and alcohol acyltransferase in saccharomycescerevisiae. Pyruvate decarboxylase is completely knocked out from an original strain, and lactate dehydrogenase is overexpressed to obtain the yeast strain with a certain capability of generating L-lactic acid; a strong promoter TEF1 is selected and adopted for overexpressing propionyl-CoA transferase, a strong promoter PGK1 is selected and adopted for overexpressing alcohol acyltransferase, witha homothallic gene HO as an integration site, a copy number of propionyl-CoA transferase is increased, the saccharomyces cerevisiae strain capable of significantly increasing the yield of ethyl lactate is obtained, and the yield of ethyl lactate obtained by using the saccharomyces cerevisiae strain reaches 353.1 mg / L; compared with the original strain, the yield of isoamyl alcohol is decreased by49.9%, the yield of phenylethyl alcohol is decreased by 59.2%, and the new method meets the higher requirements of yeast in the related field of liquor and has broad application prospects.

The present invention relates to the treatment and prevention of movement disorders with the administration of one or more propionyl-CoA precursors.

Provided are a recombinant microorganism capable of producing polylactate (PLA) or hydroxyalkanoate-lactate copolymers and a method of preparing PLA or hydroxyalkanoate-lactate copolymers using the same. The recombinant microorganism has both a gene encoding a propionyl-CoA transferase from Megasphaera elsdenii and a gene encoding a polyhydroxyalkanoate (PHA) synthase using lactyl-CoA as a substrate. A propionyl-CoA transferase from Megasphaera elsdenii is introduced into the recombinant microorganism to effectively provide lactyl-CoA, thereby enabling efficient preparation of PLA or PLA copolymers.

The present invention relates to the treatment and prevention of movement disorders with the administration of one or more propionyl-CoA precursors.

This invention relates to microorganisms that convert a carbon source to acrylate or other desirable products using propionyl-CoA as an intermediate. The invention provides genetically engineered microorganisms that carry out the conversion, as well as methods for producing acrylate by culturing the microorganisms. Also provided are microorganisms and methods for converting propionyl-CoA and propionate to 3-hydroxypropionyl-CoA, 3-hydroxypropionate (3-HP) and poly-3-hydroxypropionate.

The present invention relates to a genetically modified microorganism for the fermentative conversion of levulinic acid into propionyl-CoA and acetyl-CoA, and to a fermentation process for performing said conversion.

The invention relates to diaryl propionyl-N-methyl hydroxamic acid compounds which have a structural general formula shown in the specification. The diaryl propionyl-N-methyl hydroxamic acid compounds have a good function of inhibiting urease, and can be used for preparing medicaments for resisting gastritis, gastric ulcer, lithangiuria and the like. The invention also discloses a method for preparing the diaryl propionyl-N-methyl hydroxamic acid compounds.

The present invention provides a hydroxyacyl-coenzyme A dehydrogenase gene, an acyl-coenzyme A thiolase gene, genetically engineered strains and a use thereof. The hydroxyacyl-coenzyme A dehydrogenase gene encodes a protein (i) or (ii) as follows: (i) having an amino acid sequence according to SEQ ID NO 2; (ii) derived by substituting, deleting or inserting one or more amino acids in the amino acid sequence defined by (i) and having the same function as that of the protein of (i). The present invention constructs genetically engineered Mycobacterium strains lacking of a hydroxyacyl-coenzyme A dehydrogenase gene or an acyl-coenzyme A thiolase gene, which are used in the preparation of steroidal compounds, such as 1,4-BNA, 4-BNA, 9-OH-BNA, etc. Further, the invention improves the production efficiency and product quality of steroidal drug, improves the utilization of drug precursors, reduces the production costs, and provides the advantages of mild reaction conditions, environmentally friendly, and high economic and social benefits.

The invention provides recombinant bacteria for synthesizing succinic acid from a fixed amount of carbon dioxide, as well as a construction method and application of the recombinant bacteria, and belongs to the field of gene engineering and fermentation engineering. A recombinant bacteria host is escherichia coli, which can express a gene accADBC of acetyl-CoA carboxylase, a gene mcr of malonyl CoA reductase, a gene pcs of propionyl CoA synthase, a gene pcc of propionyl CoA carboxylase, a gene mcE of methylmalonyl-CoA isomerase, a gene mcM of methylmalonyl-CoA mutase and a gene sucCD of succinyl-coenzyme A synthase. According to the construction method, recombinant carriers pACYCDuet-accADBC-pcs and pETDuet-mcr-pcc-sucCD-mcEM are transformed into a host cell. The recombinant bacteria constructed through the construction method can adopt glucose serving as a unique carbon source to synthesize the succinic acid, and fermentation is performed for 48 hours, thus obtaining the succinic acid with the concentration of 6.06 g / L.

The invention provides a construction method and application of a metabolic engineering escherichia coli strain for producing (R)-3-hydroxybutyric acid by using acetic acid or salt thereof. The metabolic pathway is as follows: the acetic acid or salt thereof is used for producing the (R)-3-hydroxybutyric acid by using beta-ketothiolase and acetoacetyl CoA reductase, and finally the (R) 3hydroxybutyric acid is produced by using the non-specificity of propionyl CoA transferase. According to the method, a modified path is an exogenous metabolic path for producing (R)-3-hydroxybutyric acid by acetyl CoA, and the path utilizes the non-specificity of propionyl CoA transferase, so that the steps are fewer than those of the traditional path, and the energy consumption is less. According to the method, the (R)-3-hydroxybutyric acid is produced by taking acetic acid as a carbon source in escherichia coli, the yield and yield of the (R)-3-hydroxybutyric acid are improved by using different propionyl CoA transferase and host escherichia coli, and the metabolic pathway is proved to have universality in escherichia coli. According to the method, the (R)-3-hydroxybutyric acid is produced by taking the acetic acid-containing synthesis gas fermentation liquor as a culture medium through fermentation.

A metabolically engineered propionibacteria, genomically modified to express a bifunctional aldehyde / alcohol dehydrogenase identified as GenBank Gene ID: 6062148; GI: 170080868, having activity on propionyl-CoA, is prepared and used in a fermentative process to biosynthetically prepare n-propanol, propionic acid, or a combination thereof.

The invention relates to diaryl propionyl-N-methyl hydroxamic acid compounds which have a structural general formula shown in the specification. The diaryl propionyl-N-methyl hydroxamic acid compounds have a good function of inhibiting urease, and can be used for preparing medicaments for resisting gastritis, gastric ulcer, lithangiuria and the like. The invention also discloses a method for preparing the diaryl propionyl-N-methyl hydroxamic acid compounds.

The present invention discloses a method for treating a subject suffering from intermittent claudication (IC) wherein said subject takes an effective dose of propionyl L-carnitine or a pharmaceutically acceptable salt thereof and also engaging in a concomitant physical training program. The method is particular effective for patients with intermittent claudication at class II of the Leriche-Fontaine's classification. The method provides a relief from peripheral arterial disease symptoms, as shown by claudication-limited exercise tolerance, while also improving quality of life.